alprenolol has been researched along with prazosin in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (51.85) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 5 (18.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hertz, L; Subbarao, KV | 1 |
| Alexander, E; Friedman, AH | 1 |
| Larsen, PR; Raasmaja, A | 1 |
| Cornett, LE; Graham, RM; Sawutz, DG; Sena, LM | 1 |
| Coscia, E; Daw, NW; Parkinson, D | 1 |
| Klimek, V; Mogilnicka, E; Nowak, G; Wedzony, K | 1 |
| Larsen, PR; Lemack, G; Mills, I; Moolten, N; Raasmaja, A; Silva, JE | 1 |
| Agid, Y; Cash, R; Lasbennes, F; Sercombe, R; Seylaz, J | 1 |
| Wood, M | 1 |
| Brière, R; Diop, L; Grondin, L; Reader, TA | 1 |
| Bengtsson, C | 1 |
| Christoffersen, T; Jacobsen, S; Refsnes, M; Sager, G; Sand, TE; Sandnes, D; Westergren, T | 1 |
| Imai, M; Kusano, E; Nakamura, R | 1 |
| Fain, JN; Mohell, N; Wallace, M | 1 |
| Grahnén, A; Haglund, K; Lindström, B; Seideman, P; Von Bahr, C | 1 |
| Brahmadevara, N; MacDonald, A; Shaw, AM | 1 |
1 review(s) available for alprenolol and prazosin
| Article | Year |
|---|---|
Plasma drug binding: implications for anesthesiologists.
Topics: Age Factors; Alfentanil; Alprenolol; Anesthesia; Anesthetics; Blood Proteins; Bupivacaine; Burns; Cardiac Surgical Procedures; Chlorpromazine; Dipyridamole; Disopyramide; Etidocaine; Female; Fentanyl; Half-Life; Humans; Imipramine; Kidney Diseases; Lidocaine; Liver; Mathematics; Meperidine; Methadone; Myocardial Infarction; Orosomucoid; Prazosin; Pregnancy; Propranolol; Protein Binding; Quinidine; Serum Albumin; Sex Factors | 1986 |
26 other study(ies) available for alprenolol and prazosin
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of adrenergic agonists on glycogenolysis in primary cultures of astrocytes.
Topics: Alprenolol; Animals; Astrocytes; Cells, Cultured; Clonidine; Glycogen; Isoproterenol; Mice; Norepinephrine; Potassium; Prazosin; Yohimbine | 1990 |
The identification of adrenergic receptors in human pial membranes.
Topics: Alprenolol; Cerebral Veins; Dihydroalprenolol; Humans; Pia Mater; Prazosin; Receptors, Adrenergic; Yohimbine | 1990 |
Alpha 1- and beta-adrenergic agents cause synergistic stimulation of the iodothyronine deiodinase in rat brown adipocytes.
Topics: Adipose Tissue, Brown; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Alprenolol; Animals; Bucladesine; Cells, Cultured; Colforsin; Cyclic AMP; Drug Synergism; Enzyme Activation; Imidazoles; Iodide Peroxidase; Isoproterenol; Male; Norepinephrine; Phenylephrine; Prazosin; Rats; Rats, Inbred Strains; Yohimbine | 1989 |
Alpha 1-adrenergic receptor photoaffinity labeling in intact cells.
Topics: Affinity Labels; Alprenolol; Animals; Azides; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Molecular Weight; Muscle, Smooth; Photochemistry; Prazosin; Quinazolines; Receptors, Adrenergic, alpha | 1987 |
Identification and localization of adrenergic receptors in cat visual cortex.
Topics: Alprenolol; Animals; Cats; Dihydroalprenolol; Female; Male; Prazosin; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Visual Cortex; Yohimbine | 1988 |
The importance of timing for the action of alpha 1- or beta-agonists: possible relationship with the density of [3H]prazosin and [3H]dihydroalprenolol binding sites.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Alprenolol; Animals; Binding Sites; Dihydroalprenolol; Exploratory Behavior; In Vitro Techniques; Male; Prazosin; Rats; Rats, Inbred Strains; Time Factors; Tritium | 1985 |
Effect of thyroid status on catecholamine stimulation of thyroxine 5'-deiodinase in brown adipocytes.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adipose Tissue, Brown; Alprenolol; Animals; Catecholamines; Colforsin; Cycloheximide; Dactinomycin; Drug Synergism; Enzyme Activation; Hypothyroidism; Iodide Peroxidase; Isoproterenol; Kinetics; Male; Norepinephrine; Phenylephrine; Prazosin; Rats; Rats, Inbred Strains | 1989 |
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Kinetics; Parkinson Disease; Prazosin; Quinazolines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Reference Values | 1985 |
Adrenergic receptor and catecholamine distribution in rat cerebral cortex: binding studies with [3H]prazosin, [3H]idazoxan and [3H]dihydroalprenolol.
Topics: Alprenolol; Animals; Catecholamines; Cerebral Cortex; Chromatography, High Pressure Liquid; Dihydroalprenolol; Dioxanes; Dioxins; Electrochemistry; Idazoxan; Male; Prazosin; Rats; Receptors, Adrenergic; Tissue Distribution; Tritium | 1987 |
Impairment of physical performance after treatment with beta blockers and alpha blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Alprenolol; Heart Rate; Humans; Hydrochlorothiazide; Labetalol; Male; Metoprolol; Physical Exertion; Pindolol; Prazosin; Propranolol; Running | 1984 |
A comparison of the binding characteristics of the beta-adrenoceptor antagonists 3H-dihydroalprenolol and 125I-iodocyanopindolol in rat liver.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Binding, Competitive; Dihydroalprenolol; In Vitro Techniques; Iodocyanopindolol; Isoproterenol; Kinetics; Liver; Liver Regeneration; Male; Membranes; Pindolol; Prazosin; Rats; Rats, Inbred Strains | 1984 |
[Specific binding of [3H]-dihydroalprenolol and [3H]-prazosin to kidney tubules].
Topics: Alprenolol; Animals; Dihydroalprenolol; Female; Kidney Tubules; Prazosin; Quinazolines; Rabbits; Tritium | 1983 |
Alpha 1-adrenergic stimulation of phosphatidylinositol turnover and respiration of brown fat cells.
Topics: Adipose Tissue, Brown; Alprenolol; Animals; Cricetinae; Glycerol; Kinetics; Male; Mesocricetus; Oxygen Consumption; Phenylephrine; Phosphates; Phosphatidylcholines; Phosphatidylinositols; Phosphorus Radioisotopes; Prazosin; Tritium; Yohimbine | 1984 |
Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients.
Topics: Adult; Alprenolol; Blood Pressure; Drug Interactions; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; Middle Aged; Prazosin; Protein Binding; Quinazolines | 1982 |
ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Aorta, Thoracic; Binding Sites; Bupranolol; Cell Membrane; Cerebral Cortex; Dose-Response Relationship, Drug; Ethanolamines; Imidazoles; Male; Muscle, Smooth, Vascular; Phenylephrine; Pindolol; Prazosin; Propanolamines; Propranolol; Radioligand Assay; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, beta-3; Tritium; United Kingdom; Vasoconstriction | 2004 |